USPTO serial 88372290
QUELL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 16, 2020
- Examiner
- BAYLISS, HUNTER A
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with QUELL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,046*
Plus Government fees of $1,700
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Steven T. Shelton
Steven T. Shelton SHELTON IP75 SOUTH BROADWAY, SUITE 400WHITE PLAINS, NY 10601-4413UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and biological preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; veterinary preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for cell therapy, namely, preparations comprising T cells having an immunosuppressive phenotype; preparations for gene therapy; pharmaceutical, medical, and clinical preparations for use in treatment, amelioration and prophylaxis of immune system related diseases and disorders; preparations for therapies to modulate the immune system for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapies for autoimmune conditions and immunological disorders; cancer preparations, namely, chimeric antigen receptors and therapeutic preparations thereof for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; diagnostic kits consisting of monoclonal antibodies for use in disease testing and for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapeutic delivery of nucleic acids for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; viral or nucleic acid vectors for therapeutic or prophylactic purposes and preparations containing such vectors for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for genetically modifying human and animal cells for diagnostic and medical purposes; preparations of blood or cells extracted from humans or animals which have been adapted for therapeutic purposes; none of the foregoing having any relation to pain treatment or management | ACTIVE | — |
| 040 | Manufacturing and processing pharmaceuticals for others; manufacturing and processing biological, biotechnological and biopharmaceutical preparations for others; processing of biological tissue, blood, cell, and genetic material for others; production and manufacture of viral vectors for others; production and manufacture of gene therapy products for others; custom manufacture of pharmaceutical and biological preparations for others; none of the foregoing having any relation to pain treatment or management | ACTIVE | — |
| 042 | advisory services relating to gene therapy and design; Scientific and technological services, namely, research and design in the field of T cells with an immunosuppressive phenotype and transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; industrial analysis and research in the field of cell therapy; medical and veterinary research services in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new therapies in the field of autoimmune, immunological disorders and to modulate the immune system; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vectors and preparations for manipulating and adapting human and animal cells; scientific and technological services, namely, design in the field of cell therapy; none of the foregoing having any relation to pain treatment or management | ACTIVE | — |
| 044 | Medical services; medical services in the field of immunology; medical services in the field of surgery; medical services in the field of autoimmune diseases and conditions; medical services, in the field of, tissue transplant surgery; collection and preservation of biological tissue, blood, cells and genetic materials; medical diagnosis of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; Medical treatment of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; providing information and data for diagnosis and medical treatment of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; gene and nucleic acid delivery or modification for therapeutic purposes; medical treatment, namely, administering cell or gene therapies; advisory services in the field of health as it relates to cell or gene therapy; medical advisory services relating to cell or gene therapy; none of the foregoing having any relation to pain treatment or management | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Quell Therapeutics Limited
- Other trademarks owned by Quell Therapeutics Limited
- Other trademarks owned by Quell Therapeutics Limited
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named QUELL
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 16, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jan 25, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 25, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 25, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jan 25, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 25, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 25, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 16, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 31, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 31, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 11, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 25, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 25, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 25, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 25, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 25, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 13, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 13, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 13, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 23, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 23, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 23, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 30, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 30, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 30, 2019 | ALIE | ASSIGNED TO LIE | — |
| Dec 9, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 24, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 14, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 22, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 8, 2019 | NWAP | NEW APPLICATION ENTERED | — |